Form 8-K Imprimis Pharmaceuticals For: May 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Imprimis Pharma (IMMY) Misses Q1 EPS by 16c
May 12, 2016 4:56 PM EDTImprimis Pharma (NASDAQ: IMMY) reported Q1 EPS of ($0.43), $0.16 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $3.24 million.
For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.
... More